EQ.US Equillium Inc

Healthcare Biotechnology USA Stocks
1.29 USD
Close of Nov 13, 2026
0.8120 3.54
Market cap
USD 101M
P/E
-
P/B
1.84x
ROE
-36.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is EQ.US undervalued?

Graham number

The Graham number of Equillium Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Equillium Inc fundamental analysis

No fundamental analysis for Equillium Inc yet.

Equillium Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Equillium Inc

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was…

Full company profile